BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 22451929)

  • 1. Decade-long bacterial community dynamics in cystic fibrosis airways.
    Zhao J; Schloss PD; Kalikin LM; Carmody LA; Foster BK; Petrosino JF; Cavalcoli JD; VanDevanter DR; Murray S; Li JZ; Young VB; LiPuma JJ
    Proc Natl Acad Sci U S A; 2012 Apr; 109(15):5809-14. PubMed ID: 22451929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience.
    Stressmann FA; Rogers GB; van der Gast CJ; Marsh P; Vermeer LS; Carroll MP; Hoffman L; Daniels TW; Patel N; Forbes B; Bruce KD
    Thorax; 2012 Oct; 67(10):867-73. PubMed ID: 22707521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations.
    Fodor AA; Klem ER; Gilpin DF; Elborn JS; Boucher RC; Tunney MM; Wolfgang MC
    PLoS One; 2012; 7(9):e45001. PubMed ID: 23049765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Propidium Monoazide (PMA) Treatment on Mycobiome and Bacteriome Analysis of Cystic Fibrosis Airways during Exacerbation.
    Nguyen LD; Deschaght P; Merlin S; Loywick A; Audebert C; Van Daele S; Viscogliosi E; Vaneechoutte M; Delhaes L
    PLoS One; 2016; 11(12):e0168860. PubMed ID: 28030619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations.
    Zemanick ET; Harris JK; Wagner BD; Robertson CE; Sagel SD; Stevens MJ; Accurso FJ; Laguna TA
    PLoS One; 2013; 8(4):e62917. PubMed ID: 23646159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different next generation sequencing platforms produce different microbial profiles and diversity in cystic fibrosis sputum.
    Hahn A; Sanyal A; Perez GF; Colberg-Poley AM; Campos J; Rose MC; Pérez-Losada M
    J Microbiol Methods; 2016 Nov; 130():95-99. PubMed ID: 27609714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lung function and microbiota diversity in cystic fibrosis.
    Cuthbertson L; Walker AW; Oliver AE; Rogers GB; Rivett DW; Hampton TH; Ashare A; Elborn JS; De Soyza A; Carroll MP; Hoffman LR; Lanyon C; Moskowitz SM; O'Toole GA; Parkhill J; Planet PJ; Teneback CC; Tunney MM; Zuckerman JB; Bruce KD; van der Gast CJ
    Microbiome; 2020 Apr; 8(1):45. PubMed ID: 32238195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis.
    Carmody LA; Caverly LJ; Foster BK; Rogers MAM; Kalikin LM; Simon RH; VanDevanter DR; LiPuma JJ
    PLoS One; 2018; 13(3):e0194060. PubMed ID: 29522532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mild Cystic Fibrosis Lung Disease Is Associated with Bacterial Community Stability.
    Hampton TH; Thomas D; van der Gast C; O'Toole GA; Stanton BA
    Microbiol Spectr; 2021 Sep; 9(1):e0002921. PubMed ID: 34232099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Data Mining of Lung Microbiota in Cystic Fibrosis Patients.
    Li J; Hao C; Ren L; Xiao Y; Wang J; Qin X
    PLoS One; 2016; 11(10):e0164510. PubMed ID: 27741283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in cystic fibrosis airway microbiota at pulmonary exacerbation.
    Carmody LA; Zhao J; Schloss PD; Petrosino JF; Murray S; Young VB; Li JZ; LiPuma JJ
    Ann Am Thorac Soc; 2013 Jun; 10(3):179-87. PubMed ID: 23802813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measures of Cystic Fibrosis Airway Microbiota during Periods of Clinical Stability.
    Caverly LJ; Lu J; Carmody LA; Kalikin LM; Shedden K; Opron K; Azar M; Cahalan S; Foster B; VanDevanter DR; Simon RH; LiPuma JJ
    Ann Am Thorac Soc; 2019 Dec; 16(12):1534-1542. PubMed ID: 31415187
    [No Abstract]   [Full Text] [Related]  

  • 13. Changes in airway bacterial communities occur soon after initiation of antibiotic treatment of pulmonary exacerbations in cystic fibrosis.
    Carmody LA; Kalikin LM; VanDevanter DR; Li G; Opron K; Simon RH; Caverly LJ; LiPuma JJ
    J Cyst Fibros; 2022 Sep; 21(5):766-768. PubMed ID: 35667975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling the impact of antibiotic exposure on human microbiota.
    Zhao J; Murray S; Lipuma JJ
    Sci Rep; 2014 Mar; 4():4345. PubMed ID: 24614401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyrosequencing Unveils Cystic Fibrosis Lung Microbiome Differences Associated with a Severe Lung Function Decline.
    Bacci G; Paganin P; Lopez L; Vanni C; Dalmastri C; Cantale C; Daddiego L; Perrotta G; Dolce D; Morelli P; Tuccio V; De Alessandri A; Fiscarelli EV; Taccetti G; Lucidi V; Bevivino A; Mengoni A
    PLoS One; 2016; 11(6):e0156807. PubMed ID: 27355625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of inhaled aztreonam on the cystic fibrosis lung microbiome.
    Heirali AA; Workentine ML; Acosta N; Poonja A; Storey DG; Somayaji R; Rabin HR; Whelan FJ; Surette MG; Parkins MD
    Microbiome; 2017 May; 5(1):51. PubMed ID: 28476135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation.
    Bernarde C; Keravec M; Mounier J; Gouriou S; Rault G; Férec C; Barbier G; Héry-Arnaud G
    PLoS One; 2015; 10(4):e0124124. PubMed ID: 25853698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High individuality of respiratory bacterial communities in a large cohort of adult cystic fibrosis patients under continuous antibiotic treatment.
    Kramer R; Sauer-Heilborn A; Welte T; Jauregui R; Brettar I; Guzman CA; Höfle MG
    PLoS One; 2015; 10(2):e0117436. PubMed ID: 25671713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of stability and fluctuations of cultured lower airway bacterial communities in people with cystic fibrosis.
    Sherrard LJ; Einarsson GG; Johnston E; O'Neill K; McIlreavey L; McGrath SJ; Gilpin DF; Downey DG; Reid A; McElvaney NG; Boucher RC; Muhlebach MS; Elborn JS; Tunney MM
    J Cyst Fibros; 2019 Nov; 18(6):808-816. PubMed ID: 30905581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced bacterial colony count of anaerobic bacteria is associated with a worsening in lung clearance index and inflammation in cystic fibrosis.
    O'Neill K; Bradley JM; Johnston E; McGrath S; McIlreavey L; Rowan S; Reid A; Bradbury I; Einarsson G; Elborn JS; Tunney MM
    PLoS One; 2015; 10(5):e0126980. PubMed ID: 25992575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.